Johnson&Johnson

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

For immediate release

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

- *2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%**
- *2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90*
- *Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint*
- *Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, CAPLYTA for the prevention of relapse in schizophrenia, and Dual Energy THERMOCOOL SMARTTOUCH SF platform; fortifying future with data from RYBREVANT FASPRO in advanced head and neck cancer, TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma, and OTTAVA in upper abdominal procedures*

New Brunswick, N.J. (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. "Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world's toughest health challenges," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company's 140-year history."

Overall financial results

	Q2		
($ in Millions, except EPS)	**2026**	**2025**	**% Change**
Reported Sales	$25,310	$23,743	6.6%
Net Earnings	$5,534	$5,537	-0.1%
EPS (diluted)	$2.27	$2.29	-0.9%

	Q2		
Non-GAAP* ($ in Millions, except EPS)	**2026**	**2025**	**% Change**
Operational Sales[1,2]			5.6%
Adjusted Operational Sales[1,3]			5.7%
Adjusted Net Earnings[1,4]	$7,081	$6,699	5.7%
Adjusted EPS (diluted)[1,4]	$2.90	$2.77	4.7%
Free Cash Flow[5,6]	~$8,700	$6,214	

1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2 Excludes the impact of translational currency

3 Excludes the net impact of acquisitions and divestitures and translational currency

4 Excludes intangible amortization expense and special items

5 Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

6 Second-quarter YTD 2026 is estimated as of July 15, 2026

Note: values may have been rounded

Regional sales results

Q2			% Change			
($ in Millions)	2026	2025	Reported	Operational[1,2]	Currency	Adjusted Operational[1,3]
U.S.	$14,533	$13,544	7.3%	7.3	-	7.4
International	10,777	10,199	5.7	3.4	2.3	3.5
Worldwide	$25,310	$23,743	6.6%	5.6	1.0	5.7

[1] Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

[2] Excludes the impact of translational currency

[3] Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results

Q2			% Change			
($ in Millions)	2026	2025	Reported	Operational[1,2]	Currency	Adjusted Operational[1,3]
Innovative Medicine	$16,384	$15,202	7.8%	6.8	1.0	6.9
MedTech	8,926	8,541	4.5	3.6	0.9	3.7
Worldwide	$25,310	$23,743	6.6%	5.6	1.0	5.7

[1] Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

[2] Excludes the impact of translational currency

[3] Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Second-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 6.8%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 760 basis points impact) and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology.

MedTech

MedTech worldwide operational sales grew 3.6%*, with net acquisitions and divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by wound closure products and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)	July 2026	April 2026
Adjusted Operational Sales[1,2] Change vs. Prior Year / Mid-point	6.2% – 6.8% / 6.5%	5.6% – 6.6% / 6.1%
Operational Sales[2] / Mid-point Change vs. Prior Year / Mid-point	\$100.3B – \$100.9B / \$100.6B 6.5% – 7.1% / 6.8%	\$99.7B – \$100.7B / \$100.2B 5.9% – 6.9% / 6.4%
Estimated Reported Sales[3]/ Mid-point Change vs. Prior Year / Mid-point	\$100.8B – \$101.4B / \$101.1B 7.0% – 7.6% / 7.3%	\$100.3B – \$101.3B / \$100.8B 6.5% – 7.5% / 7.0%
Adjusted Operational EPS (Diluted)[2,4] / Mid-point Change vs. Prior Year / Mid-point	\$11.50 – \$11.65 / \$11.58 6.6% – 8.0% / 7.3%	\$11.30 – \$11.50 / \$11.40 4.7% – 6.7% / 5.7%
Adjusted EPS (Diluted)[3,4] / Mid-point Change vs. Prior Year / Mid-point	\$11.60 – \$11.75 / \$11.68 7.5% – 8.9% / 8.2%	\$11.45 – \$11.65 / \$11.55 6.1% – 8.1% / 7.1%

1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2 Non-GAAP financial measure; excludes the impact of translational currency

3 Calculated using Euro Average Rate: July 2026 = \$1.15 and April 2026 = \$1.17 (Illustrative purposes only)

4 Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.

Regulatory	Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform[1]	Press Release
	CHMP recommendation advances Johnson & Johnson's TECVAYLI (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma	Press Release
	FDA approves label expansion, cementing TREMFYA as the only IL-23 inhibitor proven to help stop further joint damage	Press Release
	FDA approves CAPLYTA (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia	Press Release
	Johnson & Johnson Announces CE Mark Approval for the New ETHICON 4000 Stapler	Press Release
	FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)	Press Release

Data Releases	Johnson & Johnson presents new IMAAVY (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis	Press Release
	New TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma	Press Release
	IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies	Press Release
	Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study	Press Release
	Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease	Press Release
	RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited	Press Release
	Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm	Press Release
	RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer	Press Release
	New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma	Press Release
	Johnson & Johnson study shows TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease	Press Release
	Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease	Press Release
	Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System	Press Release
	CAPLYTA (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis	Press Release
	IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)	Press Release
Product Launch	Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter	Press Release
Other	DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer[1]	Press Release
	Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida	Press Release
	Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients	Press Release
	Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform	Press Release
	DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio	Press Release
	DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO's NOVOSIS	Press Release

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation	Press Release
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations	Press Release
Johnson & Johnson Launches Landmark Head-to-Head Pulsed Field Ablation Trial in Persistent Atrial Fibrillation	Press Release
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026	Press Release

[1] Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

Note to investors concerning forward-looking statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

	SECOND QUARTER					SIX MONTHS				
			Percent Change					Percent Change		
	2026	**2025**	Total	Operations	Currency	**2026**	**2025**	Total	Operations	Currency
Sales to customers by segment of business										
Innovative Medicine										
U.S.	**$ 9,979**	**9,161**	8.9 %	8.9	-	**$ 18,850**	**17,253**	9.3 %	9.3	-
International	**6,405**	**6,041**	6.0	3.6	2.4	**12,960**	**11,822**	9.6	3.9	5.7
	16,384	**15,202**	7.8	6.8	1.0	**31,810**	**29,075**	9.4	7.1	2.3
MedTech										
U.S.	**4,554**	**4,383**	3.9	3.9	-	**9,013**	**8,596**	4.8	4.8	-
International	**4,372**	**4,158**	5.2	3.2	2.0	**8,549**	**7,965**	7.3	3.2	4.1
	8,926	**8,541**	4.5	3.6	0.9	**17,562**	**16,561**	6.0	4.1	1.9
U.S.	**14,533**	**13,544**	7.3	7.3	-	**27,863**	**25,849**	7.8	7.8	-
International	**10,777**	**10,199**	5.7	3.4	2.3	**21,509**	**19,787**	8.7	3.6	5.1
Worldwide	**$ 25,310**	**23,743**	6.6 %	5.6	1.0	**$ 49,372**	**45,636**	8.2 %	6.0	2.2

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER					SIX MONTHS				
			Percent Change					Percent Change		
	2026	**2025**	Total	Operational	Currency	**2026**	**2025**	Total	Operational	Currency
Sales to customers by geographic area										
U.S.	**$ 14,533**	**13,544**	7.3 %	7.3	-	**$ 27,863**	**25,849**	7.8 %	7.8	-
Europe	**5,726**	**5,387**	6.3	3.3	3.0	**11,574**	**10,497**	10.3	3.0	7.3
Western Hemisphere excluding U.S.	**1,309**	**1,206**	8.5	2.7	5.8	**2,602**	**2,373**	9.6	2.6	7.0
Asia-Pacific, Africa	**3,742**	**3,606**	3.8	3.9	(0.1)	**7,333**	**6,917**	6.0	4.9	1.1
International	**10,777**	**10,199**	5.7	3.4	2.3	**21,509**	**19,787**	8.7	3.6	5.1
Worldwide	**$ 25,310**	**23,743**	6.6 %	5.6	1.0	**$ 49,372**	**45,636**	8.2 %	6.0	2.2

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER				
	2026		2025		Percent
	Amount	Percent to Sales	Amount	Percent to Sales	Increase (Decrease)
Sales to customers	$ 25,310	100.0	$ 23,743	100.0	6.6
Cost of products sold	8,051	31.8	7,628	32.1	5.5
Gross Profit	17,259	68.2	16,115	67.9	7.1
Selling, marketing and administrative expenses	6,432	25.4	5,889	24.8	9.2
Research and development expense	3,653	14.4	3,516	14.8	3.9
Interest (income) expense, net	62	0.2	48	0.2	
Other (income) expense, net	331	1.3	107	0.5	
Restructuring	34	0.2	64	0.3	
Earnings before provision for taxes on income	6,747	26.7	6,491	27.3	3.9
Provision for taxes on income	1,213	4.8	954	4.0	27.1
Net earnings	$ 5,534	21.9	$ 5,537	23.3	(0.1)
Net earnings per share (Diluted)	$ 2.27		$ 2.29		(0.9)
Average shares outstanding (Diluted)	2,440.1		2,419.1		
Effective tax rate	18.0 %		14.7 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	$ 8,660	34.2	$ 8,188	34.5	5.8
Net earnings	$ 7,081	28.0	$ 6,699	28.2	5.7
Net earnings per share (Diluted)	$ 2.90		$ 2.77		4.7
Effective tax rate	18.2 %		18.2 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS				
	2026		2025		Percent
	Amount	Percent to Sales	Amount	Percent to Sales	Increase (Decrease)
Sales to customers	$ 49,372	100.0	$ 45,636	100.0	8.2
Cost of products sold	16,157	32.7	14,985	32.8	7.8
Gross Profit	33,215	67.3	30,651	67.2	8.4
Selling, marketing and administrative expenses	12,466	25.3	11,001	24.1	13.3
Research and development expense	7,180	14.5	6,741	14.8	6.5
In-process research and development impairments	36	0.1	-	-	
Interest (income) expense, net	105	0.2	(80)	(0.2)	
Other (income) expense, net	625	1.3	(7,214)	(15.8)	
Restructuring	66	0.1	81	0.2	
Earnings before provision for taxes on income	12,737	25.8	20,122	44.1	(36.7)
Provision for taxes on income	1,968	4.0	3,586	7.9	(45.1)
Net earnings	$ 10,769	21.8	$ 16,536	36.2	(34.9)
Net earnings per share (Diluted)	$ 4.41		$ 6.82		(35.3)
Average shares outstanding (Diluted)	2,443.9		2,423.3		
Effective tax rate	15.5 %		17.8 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	$ 16,481	33.4	$ 16,199	35.5	1.7
Net earnings	$ 13,695	27.7	$ 13,405	29.4	2.2
Net earnings per share (Diluted)	$ 5.60		$ 5.53		1.3
Effective tax rate	16.9 %		17.2 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Second Quarter		Six Months Ended	
(Dollars in Millions Except Per Share Data)	**2026**	**2025**	**2026**	**2025**
Net Earnings, after tax- as reported	**$5,534**	**$5,537**	**$10,769**	**$16,536**
Pre-tax Adjustments				
Litigation related	267	57	597	(6,909)
Intangible Asset Amortization expense	1,245	1,267	2,492	2,387
Restructuring related [1]	276	79	338	134
Orthopaedics separation related	258	-	377	-
Acquisition, integration and divestiture related	80	246	176	378
(Gains)/losses on securities	(213)	21	(272)	60
IPR&D impairments	-	-	36	-
Other	-	27	-	27
Tax Adjustments				
Tax impact on special item adjustments [2]	(368)	(321)	(792)	994
Tax legislation and other tax related	2	(214)	(26)	(202)
Adjusted Net Earnings , after tax	**$7,081**	**$6,699**	**$13,695**	**$13,405**
Average shares outstanding (Diluted)	2,440.1	2,419.1	2,443.9	2,423.3
Adjusted net earnings per share (Diluted)	**$2.90**	**$2.77**	**$5.60**	**$5.53**
Operational adjusted net earnings per share (Diluted)	**$2.86**		**$5.43**	

Notes:

1 In the fiscal second quarter of 2026, the Company commenced a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of 2026.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $59 million were recorded in the fiscal second quarter of 2026 ($114 million Q2 2026 YTD) and $29 million in the fiscal second quarter of 2025 ($29 million Q2 2025 YTD) and primarily include costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $17 million in the fiscal second quarter of 2026 ($24 million Q2 2026 YTD) and $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.

2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SECOND QUARTER 2026 ACTUAL vs. 2025 ACTUAL

	Segments		
	Innovative Medicine	MedTech	Total
WW As Reported	**7.8%**	**4.5%**	**6.6%**
U.S.	8.9%	3.9%	7.3%
International	6.0%	5.2%	5.7%
WW Currency	**1.0**	**0.9**	**1.0**
U.S.	-	-	-
International	2.4	2.0	2.3
WW Operational	**6.8%**	**3.6%**	**5.6%**
U.S.	8.9%	3.9%	7.3%
International	3.6%	3.2%	3.4%
All Other Acquisitions and Divestitures (A&D)	**0.1**	**0.1**	**0.1**
U.S.	0.0	0.2	0.1
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	**6.9%**	**3.7%**	**5.7%**
U.S.	8.9%	4.1%	7.4%
International	3.8%	3.2%	3.5%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SIX MONTHS 2026 ACTUAL vs. 2025 ACTUAL

	Segments		
	Innovative Medicine	**MedTech**	**Total**
WW As Reported	**9.4%**	**6.0%**	**8.2%**
U.S.	9.3%	4.8%	7.8%
International	9.6%	7.3%	8.7%
WW Currency	**2.3**	**1.9**	**2.2**
U.S.	-	-	-
International	5.7	4.1	5.1
WW Operational	**7.1%**	**4.1%**	**6.0%**
U.S.	9.3%	4.8%	7.8%
International	3.9%	3.2%	3.6%
Caplyta	**(0.9)**		**(0.6)**
U.S.	(1.6)		(1.0)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	**0.0**	**0.1**	**0.1**
U.S.	0.0	0.2	0.1
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	**6.2%**	**4.2%**	**5.5%**
U.S.	7.7%	5.0%	6.9%
International	4.1%	3.2%	3.7%

Note: Percentages are based on actual, non-rounded figures and may not sum

INNOVATIVE MEDICINE SEGMENT [2]	REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER 2026	2025	% Change Reported	% Change Operational [1]	% Change Currency	REPORTED SALES vs. PRIOR PERIOD ($MM) SIX MONTHS 2026	2025	% Change Reported	% Change Operational [1]	% Change Currency
ONCOLOGY										
US	$ 4,069	3,385	20.3%	20.3%	-	$ 7,684	6,398	20.1%	20.1%	-
Intl	3,337	2,928	14.0%	11.2%	2.8%	6,695	5,592	19.7%	13.2%	6.5%
WW	7,406	6,312	17.3%	16.1%	1.2%	14,379	11,990	19.9%	16.9%	3.0%
DARZALEX										
US	2,435	2,017	20.7%	20.7%	-	4,643	3,846	20.7%	20.7%	-
Intl	1,772	1,521	16.4%	13.5%	2.9%	3,528	2,930	20.4%	13.7%	6.7%
WW	4,207	3,539	18.9%	17.6%	1.3%	8,171	6,776	20.6%	17.7%	2.9%
CARVYKTI										
US	472	358	31.7%	31.7%	-	905	676	33.8%	33.8%	-
Intl	185	81	*	*	*	349	132	*	*	*
WW	657	439	49.4%	47.7%	1.7%	1,254	808	55.1%	52.1%	3.0%
TECVAYLI										
US	186	114	63.9%	63.9%	-	313	219	43.1%	43.1%	-
Intl	74	52	40.7%	39.2%	1.5%	148	98	51.1%	45.2%	5.9%
WW	260	166	56.5%	56.1%	0.4%	462	317	45.5%	43.7%	1.8%
TALVEY										
US	112	82	36.2%	36.2%	-	213	150	41.7%	41.7%	-
Intl	62	24	*	*	*	113	42	*	*	*
WW	174	106	63.3%	62.6%	0.7%	326	192	69.3%	67.2%	2.1%
RYBREVANT / LAZCLUZE										
US	190	139	36.8%	36.8%	-	365	252	45.0%	45.0%	-
Intl	99	41	*	*	*	181	69	*	*	*
WW	289	179	60.8%	61.6%	(0.8)%	546	320	70.4%	69.9%	0.5%
ERLEADA										
US	396	378	4.7%	4.7%	-	738	670	10.2%	10.2%	-
Intl	599	530	12.9%	9.7%	3.2%	1,206	1,009	19.4%	12.5%	6.9%
WW	995	908	9.5%	7.6%	1.9%	1,944	1,679	15.8%	11.6%	4.2%
IMBRUVICA										
US	149	239	(37.6)%	(37.6)%	-	292	474	(38.4)%	(38.4)%	-
Intl	449	496	(9.5)%	(11.8)%	2.3%	966	970	(0.4)%	(6.7)%	6.3%
WW	599	735	(18.6)%	(20.2)%	1.6%	1,259	1,444	(12.9)%	(17.1)%	4.2%
OTHER ONCOLOGY [3]										
US	131	56	*	*	-	216	110	94.5%	94.5%	-
Intl	97	181	(46.5)%	(45.7)%	(0.8)%	203	341	(40.5)%	(41.3)%	0.8%
WW	226	238	(4.6)%	(3.9)%	(0.7)%	418	452	(7.4)%	(8.0)%	0.6%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD ($MM)					REPORTED SALES vs. PRIOR PERIOD ($MM)				
	SECOND QUARTER					SIX MONTHS				
			% Change					% Change		
	2026	2025	Reported	Operational [1]	Currency	2026	2025	Reported	Operational [1]	Currency
IMMUNOLOGY										
US	$ 2,372	2,505	(5.3)%	(5.3)%	-	$ 4,227	4,701	(10.1)%	(10.1)%	-
Intl	1,473	1,489	(1.0)%	(3.5)%	2.5%	2,997	2,999	(0.1)%	(5.0)%	4.9%
WW	3,844	3,993	(3.7)%	(4.6)%	0.9%	7,224	7,700	(6.2)%	(8.1)%	1.9%
TREMFYA										
US	1,465	796	84.2%	84.2%	-	2,507	1,395	79.7%	79.7%	-
Intl	581	391	48.7%	44.2%	4.5%	1,147	747	53.6%	45.5%	8.1%
WW	2,046	1,186	72.5%	71.0%	1.5%	3,654	2,142	70.6%	67.8%	2.8%
SIMPONI / SIMPONI ARIA										
US	260	305	(14.6)%	(14.6)%	-	529	597	(11.2)%	(11.2)%	-
Intl	358	387	(7.3)%	(9.5)%	2.2%	736	753	(2.3)%	(6.9)%	4.6%
WW	618	690	(10.5)%	(11.7)%	1.2%	1,265	1,349	(6.2)%	(8.8)%	2.6%
REMICADE										
US	215	283	(24.1)%	(24.1)%	-	484	597	(19.0)%	(19.0)%	-
US Exports [4]	10	34	(71.0)%	(71.0)%	-	28	44	(37.1)%	(37.1)%	-
Intl	112	138	(18.4)%	(20.5)%	2.1%	248	281	(11.5)%	(15.4)%	3.9%
WW	338	455	(25.8)%	(26.4)%	0.6%	760	922	(17.6)%	(18.7)%	1.1%
STELARA										
US	336	1,078	(68.8)%	(68.8)%	-	556	2,059	(73.0)%	(73.0)%	-
Intl	404	575	(29.7)%	(31.1)%	1.4%	839	1,219	(31.1)%	(34.6)%	3.5%
WW	740	1,653	(55.2)%	(55.7)%	0.5%	1,396	3,278	(57.4)%	(58.7)%	1.3%
OTHER IMMUNOLOGY										
US	85	8	*	*	-	123	9	*	*	-
Intl	18	0	*	*	*	27	0	*	*	*
WW	104	8	*	*	*	150	9	*	*	*
NEUROSCIENCE										
US	1,659	1,377	20.5%	20.5%	-	3,153	2,345	34.5%	34.5%	-
Intl	678	674	0.6%	(1.1)%	1.7%	1,359	1,353	0.4%	(3.7)%	4.1%
WW	2,337	2,051	14.0%	13.4%	0.6%	4,512	3,698	22.0%	20.5%	1.5%
SPRAVATO										
US	514	366	40.7%	40.7%	-	920	642	43.4%	43.4%	-
Intl	70	50	41.2%	34.7%	6.5%	131	93	41.8%	31.9%	9.9%
WW	584	414	40.8%	40.0%	0.8%	1,052	734	43.2%	42.0%	1.2%
CAPLYTA [5]										
US	361	211	70.9%	70.9%	-	631	211	*	*	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	361	211	70.9%	70.9%	-	631	211	*	*	-
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA										
US	738	732	0.8%	0.8%	-	1,496	1,357	10.2%	10.2%	-
Intl	278	260	6.6%	5.1%	1.5%	558	537	3.7%	(0.1)%	3.8%
WW	1,015	992	2.3%	1.9%	0.4%	2,053	1,895	8.4%	7.3%	1.1%
CONCERTA / Methylphenidate										
US	12	24	(48.6)%	(48.6)%	-	34	62	(45.5)%	(45.5)%	-
Intl	133	139	(4.2)%	(4.8)%	0.6%	248	249	(0.4)%	(3.0)%	2.6%
WW	146	164	(10.8)%	(11.3)%	0.5%	282	312	(9.5)%	(11.5)%	2.0%
OTHER NEUROSCIENCE										
US	34	45	(22.9)%	(22.9)%	-	72	73	(1.1)%	(1.1)%	-
Intl	198	226	(12.3)%	(13.7)%	1.4%	422	474	(10.9)%	(15.1)%	4.2%
WW	232	270	(14.0)%	(15.2)%	1.2%	494	547	(9.6)%	(13.2)%	3.6%

See footnotes at end of schedule

	SECOND QUARTER					SIX MONTHS				
	REPORTED SALES vs. PRIOR PERIOD ($MM)					REPORTED SALES vs. PRIOR PERIOD ($MM)				
			% Change					% Change		
	2026	2025	Reported	Operational [1]	Currency	2026	2025	Reported	Operational [1]	Currency
PULMONARY HYPERTENSION (PH)										
US	$ 814	799	1.8%	1.8%	-	$ 1,645	1,543	6.5%	6.5%	-
Intl	329	314	4.9%	3.4%	1.5%	633	595	6.4%	2.3%	4.1%
WW	1,143	1,113	2.6%	2.2%	0.4%	2,278	2,138	6.5%	5.4%	1.1%
UPTRAVI										
US	386	382	1.0%	1.0%	-	771	747	3.2%	3.2%	-
Intl	108	94	15.0%	10.1%	4.9%	206	180	14.7%	7.7%	7.0%
WW	494	476	3.8%	2.8%	1.0%	977	927	5.4%	4.0%	1.4%
OPSUMIT / OPSYNVI										
US	416	403	3.2%	3.2%	-	849	766	10.9%	10.9%	-
Intl	187	180	3.9%	3.6%	0.3%	359	339	6.1%	2.7%	3.4%
WW	602	582	3.4%	3.3%	0.1%	1,208	1,104	9.4%	8.4%	1.0%
OTHER PULMONARY HYPERTENSION										
US	13	16	(16.9)%	(16.9)%	-	25	31	(19.0)%	(19.0)%	-
Intl	34	40	(14.3)%	(12.7)%	(1.6)%	68	77	(11.5)%	(12.3)%	0.8%
WW	47	55	(15.0)%	(13.9)%	(1.1)%	93	107	(13.6)%	(14.2)%	0.6%
INFECTIOUS DISEASES (ID)										
US	300	320	(6.3)%	(6.3)%	-	642	635	1.1%	1.1%	-
Intl	463	484	(4.1)%	(6.2)%	2.1%	1,010	971	4.1%	(2.5)%	6.6%
WW	763	803	(5.0)%	(6.3)%	1.3%	1,652	1,605	2.9%	(1.1)%	4.0%
EDURANT / rilpivirine										
US	3	6	(49.6)%	(49.6)%	-	10	14	(29.3)%	(29.3)%	-
Intl	347	354	(1.9)%	(3.8)%	1.9%	749	704	6.4%	(0.3)%	6.7%
WW	350	360	(2.7)%	(4.6)%	1.9%	759	718	5.7%	(0.9)%	6.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA										
US	296	312	(5.1)%	(5.1)%	-	630	617	2.1%	2.1%	-
Intl	76	85	(10.4)%	(12.8)%	2.4%	185	183	1.2%	(5.6)%	6.8%
WW	372	396	(6.3)%	(6.8)%	0.5%	815	799	1.9%	0.4%	1.5%
OTHER INFECTIOUS DISEASES										
US	1	2	(47.9)%	(47.9)%	-	2	4	(51.6)%	(51.6)%	-
Intl	40	45	(9.6)%	(12.8)%	3.2%	76	84	(9.0)%	(13.7)%	4.7%
WW	41	47	(11.6)%	(14.6)%	3.0%	78	88	(11.1)%	(15.5)%	4.4%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)										
US	765	776	(1.3)%	(1.3)%	-	1,499	1,631	(8.1)%	(8.1)%	-
Intl	124	154	(19.4)%	(21.5)%	2.1%	266	312	(14.8)%	(19.5)%	4.7%
WW	889	930	(4.3)%	(4.7)%	0.4%	1,765	1,943	(9.2)%	(9.9)%	0.7%
XARELTO										
US	664	621	7.1%	7.1%	-	1,306	1,311	(0.3)%	(0.3)%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	664	621	7.1%	7.1%	-	1,306	1,311	(0.3)%	(0.3)%	-
OTHER										
US	101	155	(35.0)%	(35.0)%	-	192	320	(39.9)%	(39.9)%	-
Intl	124	154	(19.4)%	(21.5)%	2.1%	266	312	(14.8)%	(19.5)%	4.7%
WW	225	309	(27.2)%	(28.3)%	1.1%	458	632	(27.5)%	(29.8)%	2.3%
TOTAL PH, ID, CVM										
US	1,878	1,895	(0.9)%	(0.9)%	-	3,785	3,809	(0.6)%	(0.6)%	-
Intl	916	952	(3.6)%	(5.5)%	1.9%	1,909	1,878	1.7%	(3.8)%	5.5%
WW	2,795	2,846	(1.8)%	(2.4)%	0.6%	5,694	5,686	0.1%	(1.7)%	1.8%
TOTAL INNOVATIVE MEDICINE										
US	9,979	9,161	8.9%	8.9%	-	18,850	17,253	9.3%	9.3%	-
Intl	6,405	6,041	6.0%	3.6%	2.4%	12,960	11,822	9.6%	3.9%	5.7%
WW	$ 16,384	15,202	7.8%	6.8%	1.0%	$ 31,810	29,075	9.4%	7.1%	2.3%

See footnotes at end of schedule

MEDTECH SEGMENT [2]	SECOND QUARTER 2026	2025	% Change Reported	Operational [1]	Currency	SIX MONTHS 2026	2025	% Change Reported	Operational [1]	Currency
	REPORTED SALES vs. PRIOR PERIOD ($MM)					REPORTED SALES vs. PRIOR PERIOD ($MM)				
CARDIOVASCULAR										
US	$ 1,426	1,364	4.5%	4.5%	-	$ 2,825	2,625	7.6%	7.6%	-
Intl	978	948	3.2%	1.1%	2.1%	1,956	1,790	9.3%	5.2%	4.1%
WW	2,404	2,313	4.0%	3.1%	0.9%	4,781	4,416	8.3%	6.6%	1.7%
ELECTROPHYSIOLOGY										
US	783	741	5.8%	5.8%	-	1,519	1,425	6.6%	6.6%	-
Intl	749	728	2.9%	0.4%	2.5%	1,502	1,366	10.0%	5.6%	4.4%
WW	1,533	1,468	4.4%	3.1%	1.3%	3,022	2,791	8.3%	6.2%	2.1%
ABIOMED										
US	342	360	(4.8)%	(4.8)%	-	731	699	4.6%	4.6%	-
Intl	97	89	9.5%	9.2%	0.3%	197	170	16.1%	11.4%	4.7%
WW	440	448	(2.0)%	(2.0)%	0.0%	928	868	6.8%	5.9%	0.9%
SHOCKWAVE										
US	268	233	14.6%	14.6%	-	510	439	16.1%	16.1%	-
Intl	67	58	14.5%	15.4%	(0.9)%	130	110	17.7%	17.2%	0.5%
WW	335	292	14.6%	14.7%	(0.1)%	640	550	16.4%	16.3%	0.1%
OTHER CARDIOVASCULAR										
US	33	31	5.5%	5.5%	-	65	63	3.1%	3.1%	-
Intl	65	72	(10.5)%	(13.2)%	2.7%	127	144	(11.9)%	(15.3)%	3.4%
WW	98	104	(5.7)%	(7.5)%	1.8%	192	207	(7.4)%	(9.7)%	2.3%
SURGERY										
US	1,094	1,043	5.0%	5.0%	-	2,140	2,045	4.7%	4.7%	-
Intl	1,559	1,512	3.1%	0.5%	2.6%	3,024	2,906	4.1%	(0.3)%	4.4%
WW	2,653	2,555	3.9%	2.3%	1.6%	5,164	4,951	4.3%	1.8%	2.5%
ADVANCED										
US	499	477	4.7%	4.7%	-	976	934	4.5%	4.5%	-
Intl	691	687	0.5%	(1.9)%	2.4%	1,337	1,303	2.6%	(1.4)%	4.0%
WW	1,189	1,164	2.2%	0.8%	1.4%	2,312	2,237	3.4%	1.0%	2.4%
GENERAL										
US	596	567	5.2%	5.2%	-	1,165	1,111	4.8%	4.8%	-
Intl	868	825	5.3%	2.5%	2.8%	1,687	1,603	5.2%	0.7%	4.5%
WW	1,464	1,391	5.2%	3.6%	1.6%	2,852	2,714	5.1%	2.4%	2.7%

See footnotes at end of schedule

	SECOND QUARTER					SIX MONTHS				
	REPORTED SALES vs. PRIOR PERIOD ($MM)					REPORTED SALES vs. PRIOR PERIOD ($MM)				
			% Change					% Change		
	2026	2025	Reported	Operational (1)	Currency	2026	2025	Reported	Operational (1)	Currency
VISION										
US	$ 565	557	1.4%	1.4%	-	$ 1,144	1,123	1.9%	1.9%	-
Intl	887	813	9.1%	8.5%	0.6%	1,672	1,526	9.6%	6.7%	2.9%
WW	1,451	1,369	6.0%	5.6%	0.4%	2,816	2,648	6.3%	4.6%	1.7%
CONTACT LENSES / OTHER										
US	445	429	3.6%	3.6%	-	913	881	3.7%	3.7%	-
Intl	580	536	8.1%	7.9%	0.2%	1,081	1,003	7.7%	5.0%	2.7%
WW	1,025	965	6.1%	6.0%	0.1%	1,994	1,884	5.8%	4.4%	1.4%
SURGICAL										
US	120	128	(6.0)%	(6.0)%	-	231	242	(4.5)%	(4.5)%	-
Intl	306	277	10.9%	9.6%	1.3%	591	523	13.1%	9.8%	3.3%
WW	426	403	5.6%	4.7%	0.9%	822	764	7.5%	5.3%	2.2%
ORTHOPAEDICS										
US	1,470	1,420	3.5%	3.5%	-	2,905	2,804	3.6%	3.6%	-
Intl	948	885	7.2%	5.3%	1.9%	1,896	1,742	8.9%	3.9%	5.0%
WW	2,418	2,305	4.9%	4.2%	0.7%	4,801	4,546	5.6%	3.7%	1.9%
HIPS										
US	283	271	4.6%	4.6%	-	560	534	4.9%	4.9%	-
Intl	158	150	5.5%	3.0%	2.5%	317	296	7.2%	1.7%	5.5%
WW	441	421	4.9%	4.0%	0.9%	877	830	5.7%	3.8%	1.9%
KNEES										
US	228	226	1.1%	1.1%	-	467	457	2.2%	2.2%	-
Intl	182	164	11.4%	10.3%	1.1%	363	322	13.0%	8.4%	4.6%
WW	410	389	5.5%	5.0%	0.5%	830	778	6.7%	4.8%	1.9%
TRAUMA										
US	536	501	6.7%	6.7%	-	1,068	1,003	6.4%	6.4%	-
Intl	291	267	9.2%	7.4%	1.8%	592	537	10.3%	5.2%	5.1%
WW	827	768	7.6%	6.9%	0.7%	1,660	1,540	7.8%	6.0%	1.8%
SPINE, SPORTS & OTHER										
US	423	422	0.2%	0.2%	-	810	810	0.0%	0.0%	-
Intl	317	305	4.0%	1.9%	2.1%	624	588	6.1%	1.3%	4.8%
WW	740	727	1.8%	0.9%	0.9%	1,434	1,398	2.6%	0.6%	2.0%
TOTAL MEDTECH										
US	4,554	4,383	3.9%	3.9%	-	9,013	8,596	4.8%	4.8%	-
Intl	4,372	4,158	5.2%	3.2%	2.0%	8,549	7,965	7.3%	3.2%	4.1%
WW	$ 8,926	8,541	4.5%	3.6%	0.9%	$ 17,562	16,561	6.0%	4.1%	1.9%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

Quarter to Date

Innovative Medicine	**Second Quarter June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Second Quarter June 28, 2026 Non-GAAP**
Cost of products sold	$ 4,296	(764)		(18)	(9)				3,505
Selling, marketing and admin expenses	3,130								3,130
Research and development expense	2,875								2,875
Other segment items	(166)		91	(182)	(54)	227			(84)
Adjusted Income Before Tax by Segment	6,249	764	(91)	200	63	(227)	-	-	6,958

MedTech	**Second Quarter June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Second Quarter June 28, 2026 Non-GAAP**
Cost of products sold	$ 3,737	(481)		(17)			(3)		3,236
Selling, marketing and admin expenses	3,069						(17)		3,052
Research and development expense	778						(2)		776
Other segment items	165		76	(59)	(37)	(14)	(236)		(105)
Adjusted Income Before Tax by Segment	1,177	481	(76)	76	37	14	258	-	1,967

Expenses not allocated to segments	**Second Quarter June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Second Quarter June 28, 2026 Non-GAAP**
Cost of products sold	$ 18								18
Selling, marketing and admin expenses	233								233
Research and development expense	-								-
Other segment items	428		(434)		20				14
Adjusted Income Before Tax by Segment	(679)	-	434	-	(20)	-	-	-	(265)

Johnson & Johnson Consolidated	**Second Quarter June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Second Quarter June 28, 2026 Non-GAAP**
Cost of products sold	$ 8,051	(1,245)		(35)	(9)		(3)		6,759
Selling, marketing and admin expenses	6,432						(17)		6,415
Research and development expense	3,653						(2)		3,651
Other (Income) / Expense	331		(267)	(207)	(71)	213	(236)		(237)
In-process research and development impairments	-								-
Interest (Income)/Expense	62								62
Restructuring	34			(34)					-
Adjusted Income Before Tax	6,747	1,245	267	276	80	(213)	258	-	8,660
Provision for taxes on income	1,213	239	59	54	23	(50)	43	(2)	1,579
Net Earnings	$ 5,534	1,006	208	222	57	(163)	215	2	7,081

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

Quarter to Date

Innovative Medicine	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	$ 3,978	(785)			(13)				3,180
Selling, marketing and admin expenses	2,789								2,789
Research and development expense	2,869								2,869
Other segment items	14		69		(207)	8		(13)	(129)
Adjusted Income Before Tax by Segment	5,552	785	(69)	-	220	(8)	-	13	6,493

MedTech	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	$ 3,638	(482)		(15)	1				3,142
Selling, marketing and admin expenses	2,862								2,862
Research and development expense	647				43				690
Other segment items	190		(83)	(64)	(53)	(29)		(14)	(53)
Adjusted Income Before Tax by Segment	1,204	482	83	79	9	29	-	14	1,900

Expenses not allocated to segments	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	$ 12								12
Selling, marketing and admin expenses	238								238
Research and development expense	-								-
Other segment items	15		(43)		(17)				(45)
Adjusted Income Before Tax by Segment	(265)	-	43	-	17	-	-	-	(205)

Johnson & Johnson Consolidated	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	$ 7,628	(1,267)		(15)	(12)				6,334
Selling, marketing and admin expenses	5,889								5,889
Research and development expense	3,516				43				3,559
Other (Income) / Expense	107		(57)		(277)	(21)		(27)	(275)
In-process research and development impairments	-								-
Interest (Income)/Expense	48								48
Restructuring	64			(64)					-
Adjusted Income Before Tax	6,491	1,267	57	79	246	21	-	27	8,188
Provision for taxes on income	954	222	9	13	72	5	214	-	1,489
Net Earnings	$ 5,537	1,045	48	66	174	16	(214)	27	6,699

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

Year to Date

Innovative Medicine	**Six Months June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**In-process research and development impairments**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Six Months June 28, 2026 Non-GAAP**
Cost of products sold	$ 8,686	(1,527)			(18)	(19)				7,122
Selling, marketing and admin expenses	6,048									6,048
Research and development expense	5,688									5,688
Other segment items	(178)		51		(182)	(100)	282			(127)
Adjusted Income Before Tax by Segment	11,566	1,527	(51)	-	200	119	(282)	-	-	13,079

MedTech	**Six Months June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**In-process research and development impairments**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Six Months June 28, 2026 Non-GAAP**
Cost of products sold	$ 7,438	(965)			(42)			(3)		6,428
Selling, marketing and admin expenses	5,975							(17)		5,958
Research and development expense	1,492							(2)		1,490
Other segment items	241		117	(36)	(96)	(64)	(10)	(355)		(203)
Adjusted Income Before Tax by Segment	2,416	965	(117)	36	138	64	10	377	-	3,889

Expenses not allocated to segments	**Six Months June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**In-process research and development impairments**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Six Months June 28, 2026 Non-GAAP**
Cost of products sold	$ 33									33
Selling, marketing and admin expenses	443									443
Research and development expense	-									-
Other segment items	769		(765)			7				11
Adjusted Income Before Tax by Segment	(1,245)	-	765	-	-	(7)	-	-	-	(487)

Johnson & Johnson Consolidated	**Six Months June 28, 2026 GAAP**	**Intangible asset amortization**	**Litigation related**	**In-process research and development impairments**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Orthopaedics Separation Related**	**Tax legislation and other tax related**	**Six Months June 28, 2026 Non-GAAP**
Cost of products sold	$ 16,157	(2,492)			(60)	(19)		(3)		13,583
Selling, marketing and admin expenses	12,466							(17)		12,449
Research and development expense	7,180							(2)		7,178
Other (Income) / Expense	625		(597)		(212)	(157)	272	(355)		(424)
In-process research and development impairments	36			(36)						-
Interest (Income)/Expense	105									105
Restructuring	66				(66)					-
Adjusted Income Before Tax	12,737	2,492	597	36	338	176	(272)	377	-	16,481
Provision for taxes on income	1,968	479	131	8	124	45	(63)	68	26	2,786
Net Earnings	$ 10,769	2,013	466	28	214	131	(209)	309	(26)	13,695

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

Year to Date

Innovative Medicine	**Six Months June 29, 2025 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Tax legislation and other tax related**	**Other**	**Six Months June 29, 2025 Non-GAAP**
Cost of products sold	$ 7,998	(1,434)			(13)				6,551
Selling, marketing and admin expenses	5,050								5,050
Research and development expense	5,417								5,417
Other segment items	(152)	-	69		(227)	(10)		(13)	(333)
Adjusted Income Before Tax by Segment	10,762	1,434	(69)	-	240	10	-	13	12,390

MedTech	**Six Months June 29, 2025 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Tax legislation and other tax related**	**Other**	**Six Months June 29, 2025 Non-GAAP**
Cost of products sold	$ 6,964	(953)		(23)	(51)				5,937
Selling, marketing and admin expenses	5,518								5,518
Research and development expense	1,324				37				1,361
Other segment items	130		(83)	(111)	(107)	(50)		(14)	(235)
Adjusted Income Before Tax by Segment	2,625	953	83	134	121	50	-	14	3,980

Expenses not allocated to segments	**Six Months June 29, 2025 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Tax legislation and other tax related**	**Other**	**Six Months June 29, 2025 Non-GAAP**
Cost of products sold	$ 23								23
Selling, marketing and admin expenses	433								433
Research and development expense	-								-
Other segment items	(7,191)		6,923		(17)				(285)
Adjusted Income Before Tax by Segment	6,735	-	(6,923)	-	17	-	-	-	(171)

Johnson & Johnson Consolidated	**Six Months June 29, 2025 GAAP**	**Intangible asset amortization**	**Litigation related**	**Restructuring related**	**Acquisition, integration and divestiture related**	**(Loss)/gain on securities**	**Tax legislation and other tax related**	**Other**	**Six Months June 29, 2025 Non-GAAP**
Cost of products sold	$ 14,985	(2,387)		(23)	(64)				12,511
Selling, marketing and admin expenses	11,001								11,001
Research and development expense	6,741				37				6,778
Other (Income) / Expense	(7,214)		6,909	(30)	(351)	(60)		(27)	(773)
In-process research and development impairments	-								-
Interest (Income)/Expense	(80)								(80)
Restructuring	81			(81)					-
Adjusted Income Before Tax	20,122	2,387	(6,909)	134	378	60	-	27	16,199
Provision for taxes on income	3,586	410	(1,544)	24	102	14	202		2,794
Net Earnings	$ 16,536	1,977	(5,365)	110	276	46	(202)	27	13,405